

JUBILANT PHARMA LIMITED
(Company Registration No. 200506887H)
(Incorporated in the Republic of Singapore)
Registered office: 160 Robinson Road, #17-01 SBF Center, Singapore 068914

July 20, 2018

Singapore Exchange Securities Trading Limited
11 North Buona Vista Drive #06-07
The Metropolis Tower 2
Singapore 138589

Dear Sirs,

We enclose a communication pertaining to I-131 MIBG OPTIMUM Trials.

This is for your kind information and records.

Thanking You,

Yours faithfully,
For Jubilant Pharma Limited



Sanjay Bhartia
Chief Financial Officer

**Jubilant Pharma Ltd.**

6 Temasek Boulevard, #20-06
Suntec City Tower Four, Singapore 038986
Tel.: +65 6235 4129
www.jubilantpharma.com

Jubilant initiates I-131 MIBG OPTIMUM Trials

Noida (UP), India, Friday, July 20, 2018

Jubilant Pharma Limited, a material wholly owned subsidiary of Jubilant Life Sciences Ltd, through one of its wholly owned subsidiaries, has initiated OPTIMUM trial which is a Pivotal Phase II Clinical Trial designed to prove the safety and effectiveness of I-131 MIBG for the treatment of neuroblastoma. The study will include both male and female patients over the age of one year who show a return or persistence of this disease following initial therapy. Children enrolled in the OPTIMUM trial could receive up to two dose cycles of I-131 MIBG over a twenty-six week period.

The information collected from this study will be submitted to the United States Food and Drug Administration (FDA) under the Orphan Drug Designation program and is eligible for accelerated approval if the clinical trials are successful. Jubilant's MIBG has already been used for over a decade in USFDA approved expanded access trials and two Pediatric Oncology academic consortiums – NANT (New Approaches to Neuroblastoma Therapy) and COG (Children's Oncology Group).

Commenting on the occasion, **Mr. Shyam S. Bhartia, Chairman and Managing Director and Mr. Hari S. Bhartia, Co-Chairman and Director, Jubilant Life Sciences Limited** said: "We are extremely pleased that JDI can offer these critical therapeutic options to children who suffer from this rare cancer. The initiation of this pivotal trial is a crucial step for Jubilant's MIBG NDA filing and is a testimony to our Specialty R&D capability to develop complex products addressing advanced medical needs."

About Jubilant Pharma Limited

Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non Sterile products. JPL has 6 USFDA approved manufacturing facilities in India, US and Canada and R&D centres in India and Canada and a network of over 50 radio-pharmacies in the US. The Company has a team of around 4,300 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.